Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Background and Purpose—In the Secondary Prevention of Small Subcortical Strokes
(SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …

Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. However, protection with antiplatelet therapy in people with a high …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Objectives Whether clopidogrel should be added to aspirin for stroke prevention remained
controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to …